LEADER 01604nam  2200505   450 
001 9910151711703321
005 20230809233524.0
010   $a1-119-09741-X
010   $a1-78785-145-1
010   $a1-119-09740-1
010   $a1-119-09744-4
035   $a(CKB)4330000000008499
035   $a(Au-PeEL)EBL4753453
035   $a(CaPaEBR)ebr11308591
035   $a(CaONFJC)MIL971746
035   $a(OCoLC)963934725
035   $a(MiAaPQ)EBC4753453
035   $a(EXLCZ)994330000000008499
100   $a20161215h20172017  uy             0
101 0 $aeng
135   $aurcnu||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aDrug safety evaluation /$fShayne Cox Gad
205   $aThird edition.
210  1$aHoboken, New Jersey :$cWiley,$d2017.
210  4$dİ2017
215   $a1 online resource (917 pages) $cillustrations, tables
311   $a1-119-09739-8 
320   $aIncludes bibliographical references at the end of each chapters and index.
330   $a"Provides practical guidance to solve scientific and regulatory issues in preclinical safety assessment, early clinical drug development, and post-approval impurity issues"--$cProvided by publisher.
606   $aDrugs$xToxicology
606   $aDrugs$xTesting
615  0$aDrugs$xToxicology.
615  0$aDrugs$xTesting.
676   $a615.9
700   $aGad$b Shayne C.$f1948-$096171
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910151711703321
996   $aDrug Safety Evaluation$9832475
997   $aUNINA